CYTK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cytokinetics Inc (CYTK) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has strong growth potential and positive catalysts such as Myqorzo's launch and analyst optimism, the stock's recent price trend, hedge fund selling, and lack of immediate trading signals suggest a cautious approach. Holding the stock or waiting for a better entry point may be more prudent.
The technical indicators are mixed. The MACD is positive and expanding, suggesting bullish momentum. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 63.953. However, RSI is neutral at 54.761, and the stock has a 40% chance of declining in the short term based on candlestick analysis.
Strong analyst ratings and price target increases, with multiple firms maintaining Buy or Overweight ratings and targets as high as $
Positive sentiment around Myqorzo's launch and its differentiated label, which positions it well in the market.
Revenue growth of 318.14% YoY in Q3 2025, indicating strong operational performance.
Hedge funds are aggressively selling, with a 5964.05% increase in selling activity over the last quarter.
The stock declined 2.63% in the regular market session and has a short-term bearish trend based on candlestick analysis.
Net income remains negative (-$306.18M in Q3 2025), and EPS is still in the red (-2.55).
In Q3 2025, the company showed strong revenue growth of 318.14% YoY, reaching $1.94M. Net income improved by 90.71% YoY but remains negative at -$306.18M. EPS also improved by 87.50% YoY but is still negative at -2.55. Gross margin remains at 100%. While growth trends are positive, the company is not yet profitable.
Analysts are optimistic about Cytokinetics, with multiple firms raising price targets recently. Targets range from $66 to $108, with most firms maintaining Buy or Overweight ratings. Analysts highlight the strong potential of Myqorzo and upcoming catalysts, such as the Phase 3 ACACIA trial results in early Q2 2026.
